Background : Prediction of treatment response in patients of chronicHCV infection is a crucial issue particularly with the current poorresponse rate, cost and side effects of therapy in addition to the uniqueability of HCV to escape the host immune response. Chemokines areimportant determinants of the different stages of the chronic HCVinfection-associated liver disease and many have been reported to beassociated with the outcome of inflammation and treatment response.Aim of the work: The aim of this study was to assess the serumlevels of certain chemokines and the adhesion molecule E-Cadherin todetermine the influence of therapy on chemokines and their relationshipwith the outcome of treatment. In other words, to determine whether these chemokines can be used as non-invasive markers for the response totherapy, and as monitors for the outcome of treatment.Methods : Fifty seven biopsy proven chronic HCV patients wererecruited for PEG-IFN alpha and ribavirin therapy, for whom routineinvestigations, RT-PCR, serum chemokines levels (CXCL5, CXCL9,CXCL11, CXCL12, CXCL13, CXCL16) and the adhesion molecule Ecadherinwere done at baseline and after 12 and 24 weeks. Follow up wasdone at different treatment endpoints to assess treatment response.Results : The serum levels of CXCL5, CXCL11, CXCL13 and CXCL16 before treatment and at weeks 12 and 24 showed significantchanges with time but with no significant differences between respondersand non responders. However serum E-Cadherin levels of patients atweek 12 showed significant differences between responders and nonresponders.